(NASDAQ: SYRS) Syros Pharmaceuticals's forecast annual revenue growth rate of 89.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.69%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Syros Pharmaceuticals's revenue in 2023 is $23,436,000.On average, 4 Wall Street analysts forecast SYRS's revenue for 2023 to be $324,626,032, with the lowest SYRS revenue forecast at $161,807,368, and the highest SYRS revenue forecast at $436,879,894. On average, 2 Wall Street analysts forecast SYRS's revenue for 2024 to be $1,202,431,003, with the lowest SYRS revenue forecast at $212,372,171, and the highest SYRS revenue forecast at $2,192,489,836.
In 2025, SYRS is forecast to generate $3,385,616,916 in revenue, with the lowest revenue forecast at $750,381,669 and the highest revenue forecast at $8,579,835,688.